Literature DB >> 7527588

Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR.

L Zhou1, C R Dey, S E Wert, M D DuVall, R A Frizzell, J A Whitsett.   

Abstract

Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). A potential animal model of CF, the CFTR-/- mouse, has had limited utility because most mice die from intestinal obstruction during the first month of life. Human CFTR (hCFTR) was expressed in CFTR-/- mice under the control of the rat intestinal fatty acid-binding protein gene promoter. The mice survived and showed functional correction of ileal goblet cell and crypt cell hyperplasia and cyclic adenosine monophosphate-stimulated chloride secretion. These results support the concept that transfer of the hCFTR gene may be a useful strategy for correcting physiologic defects in patients with CF.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527588     DOI: 10.1126/science.7527588

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  98 in total

1.  CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation.

Authors:  Torsten H Schroeder; Martin M Lee; Patrick W Yacono; Carolyn L Cannon; A Alev Gerçeker; David E Golan; Gerald B Pier
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

2.  In vivo alterations of IFN regulatory factor-1 and PIAS1 protein levels in cystic fibrosis epithelium.

Authors:  T J Kelley; H L Elmer
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

3.  Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses.

Authors:  Christian Mueller; Sofia A Braag; Allison Keeler; Craig Hodges; Mitchell Drumm; Terence R Flotte
Journal:  Am J Respir Cell Mol Biol       Date:  2010-08-19       Impact factor: 6.914

4.  Complementation of null CF mice with a human CFTR YAC transgene.

Authors:  A L Manson; A E Trezise; L J MacVinish; K D Kasschau; N Birchall; V Episkopou; G Vassaux; M J Evans; W H Colledge; A W Cuthbert; C Huxley
Journal:  EMBO J       Date:  1997-07-16       Impact factor: 11.598

Review 5.  Genetic therapies for cystic fibrosis lung disease.

Authors:  Patrick L Sinn; Reshma M Anthony; Paul B McCray
Journal:  Hum Mol Genet       Date:  2011-03-21       Impact factor: 6.150

6.  Cystic fibrosis transmembrane conductance regulator with a shortened R domain rescues the intestinal phenotype of CFTR-/- mice.

Authors:  Lynda S Ostedgaard; David K Meyerholz; Daniel W Vermeer; Philip H Karp; Lindsey Schneider; Curt D Sigmund; Michael J Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-01       Impact factor: 11.205

Review 7.  Animal models for cystic fibrosis liver disease (CFLD).

Authors:  Romina Fiorotto; Mariangela Amenduni; Valeria Mariotti; Massimiliano Cadamuro; Luca Fabris; Carlo Spirli; Mario Strazzabosco
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-07-30       Impact factor: 5.187

8.  Processing and function of CFTR-DeltaF508 are species-dependent.

Authors:  Lynda S Ostedgaard; Christopher S Rogers; Qian Dong; Christoph O Randak; Daniel W Vermeer; Tatiana Rokhlina; Philip H Karp; Michael J Welsh
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-14       Impact factor: 11.205

9.  Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes.

Authors:  William R Hunt; Susu M Zughaier; Dana E Guentert; Melissa A Shenep; Michael Koval; Nael A McCarty; Jason M Hansen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-10-04       Impact factor: 5.464

10.  Endogenous expression of type II cGMP-dependent protein kinase mRNA and protein in rat intestine. Implications for cystic fibrosis transmembrane conductance regulator.

Authors:  T Markert; A B Vaandrager; S Gambaryan; D Pöhler; C Häusler; U Walter; H R De Jonge; T Jarchau; S M Lohmann
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.